Review of current treatment of sacral chordoma.
Chordoma is a relatively rare, locally aggressive tumor which is known to arise from embryonic remnants of the notochord and to occur exclusively along the spinal axis, with a predilection for the sacrum. Although chordoma typically presents as a single lesion, a few cases of metastasis have been reported and the prognosis of such patients may be poor. Chordomas are slowly growing tumors with insidious onset of symptoms, making early diagnosis difficult. Recent improvements in imaging have provided valuable information for early diagnosis. The optimal treatment for sacral chordoma is en bloc sacral resection with wide surgical margins. Improvement in surgical techniques has widened the opportunities to provide effective treatment. However, the effects of adjuvant treatment options are still both unclear and controversial. Substantial progress has been made in the study of molecular-targeted therapy. The authors review the current surgical and adjuvant treatment modalities, including molecular-targeted therapy, available for management of sacral chordoma.
Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Kang-wu
KW
Chen
Hui-lin
HL
Yang
Yugandhar
Y
Kandimalla
Jia-yong
JY
Liu
Gen-lin
GL
Wang
D002817:Chordoma / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D012447:Sacrum; D013125:Spinal Neoplasms / Q000628:therapy*; D016896:Treatment Outcome